Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Shore on the Rationale for the Phase 3 HERO Trial in Advanced Prostate Cancer

June 22nd 2020

Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.

Saad Highlights Striking Survival Benefit With Apalutamide in nmCRPC

June 22nd 2020

The addition of apalutamide to androgen deprivation therapy, significantly improved overall survival and metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Sokolova on the Rationale for Systematic Implementation of Germline Testing for Metastatic Prostate Cancer

June 19th 2020

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.

Dr. Morris on Deciding Among PET Tracers in Prostate Cancer

June 19th 2020

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

Dr. Kelly on Identifying Optimal Dose of Radium-223 and Niraparib in mCRPC

June 19th 2020

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Dr. Klein on Challenges With Active Surveillance in Prostate Cancer

June 19th 2020

Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.

Ipatasertib/Abiraterone Regimen Improves Radiographic PFS in mCRPC With PTEN Loss

June 19th 2020

The combination of ipatasertib plus abiraterone acetate and prednisone/prednisolone improved radiographic progression-free survival compared with standard treatment plus placebo in patients with metastatic castration-resistant prostate cancer who have PTEN loss.

Guidelines Recommend Widespread Genetic Testing for Metastatic Prostate Cancer, Associated Family History Risk

June 18th 2020

The first multidisciplinary, consensus-driven framework for genetic testing in prostate cancer was borne out of the 2019 Philadelphia Prostate Cancer Consensus Conference, leading to the creation of comprehensive guidelines regarding the evaluation, management, and implementation therein.

Dr. Katz on the Oncotype DX GPS Assay in Prostate Cancer

June 18th 2020

Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.

Dr. Awad on Objectives of the Phase 2 GEOMETRY Mono-1 Study in NSCLC

June 18th 2020

Mark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).

Dr. Sartor on Outcomes With 177Lu-PSMA-617 After Radium-223 in mCRPC

June 18th 2020

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.

Dr. Sartor on Sequential Use of Beta and Alpha Emitters in mCRPC

June 17th 2020

A. Oliver Sartor, MD, discusses the rationale for investigating the sequential use of beta emitters and alpha emitters in metastatic castration-resistant prostate cancer.

Dr. Chi on the Rationale for the PC-BETS Study With ctDNA in Prostate Cancer

June 16th 2020

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, discusses clinical challenges in prostate cancer.

Dr. Morris on the Promise of PSMA-Targeted PET Imaging in Prostate Cancer

June 15th 2020

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

PSMA-Targeted PET Tracer Shows Increased Diagnostic Performance in Prostate Cancer

June 15th 2020

Michael J. Morris, MD, discusses the results of the CONDOR trial and the utility of PSMA-targeted PET imaging in prostate cancer.

Study Exposes Severe Lack of Diversity in Prostate Cancer Clinical Trials

June 11th 2020

Prostate cancer has been known to show clear racial disparities, with men of African descent comprising the vast majority of cases.

Dr. Saad on the SPARTAN Trial in M0CRPC

June 10th 2020

Fred Saad, MD, FRCS, discusses the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Dr. Kelly on Efficacy of Radium-223 Dichloride and Niraparib in Patients With mCRPC

June 10th 2020

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPC

June 9th 2020

William K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Dr. Morris on Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer

June 5th 2020

Michael J. Morris, MD, discusses the impact of prostate-specific membrane antigen-targeted imaging with 18F-DCFPyL-PET/CT on the clinical management of patients with prostate cancer.